Research summary
Almost half of Canadians will develop cancer during their lifetimes, and a quarter of Canadians are likely to die from the disease. As Canada Research Chair in Pharmacogenomics, Dr. Chantal Guillemette aims to improve cancer therapies by better predicting drug responses.
Guillemette and her research team are exploring the role of the genome and metabolome as possible predictive tools, since they both influence the behaviours of cancer cells. They are also investigating the underlying molecular and biological mechanisms that determine why various cancers progress and respond differently to drugs. Ultimately, they hope to offer insights and new targets to improve cancer treatment. Their findings may also lead to more effective strategies to identify and treat high-risk cancers.